Moderna (MRNA)
(Real Time Quote from BATS)
$24.97 USD
+0.13 (0.52%)
Updated Sep 17, 2025 11:30 AM ET
3-Hold of 5 3
F Value D Growth B Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
MRNA 24.97 +0.13(0.52%)
Will MRNA be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for MRNA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for MRNA
MRNA Stock Rises as Updated COVID-19 Jab Shows Strong Immune Response
Vertex Plunges Around 24% in Six Months: How to Play the Stock
MRNA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Will GSK Be Able to Resolve Its Vaccine Challenges Anytime Soon?
COVID-19 Vaccine Stocks Fall on Reports Linking Shots to Child Deaths
Moderna (MRNA) Declines More Than Market: Some Information for Investors
Other News for MRNA
U.S. health insurers pledge continuing coverage of COVID shots ahead of ACIP meeting
Former CDC Director Monarez says RFK Jr. fired her for not following two directives
Is MRNA showing upside potential? Directional Movement Crossover Bullish shows up after climbing 4.02%
VOO ETF News, 9/17/2025
SPY ETF News, 9/17/2025